Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age

PURPOSE: To determine the impact of initiating enzyme replacement therapy (ERT) with agalsidase alfa early in the course of Fabry disease, we evaluated renal and cardiac outcomes for ≤10 years after ERT initiation in males from the Fabry Outcome Survey (FOS). PATIENTS AND METHODS: Male patients from...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Drug Des Devel Ther
Hlavní autoři: Parini, Rossella, Pintos-Morell, Guillem, Hennermann, Julia B, Hsu, Ting-Rong, Karabul, Nesrin, Kalampoki, Vasiliki, Gurevich, Andrey, Ramaswami, Uma
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7276893/
https://ncbi.nlm.nih.gov/pubmed/32581513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S249433
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky